Cellectis Targets 2028 BLA Submission for Lasme-cel Following Pivotal Phase 2 Interim Data

With a BLA submission for lasme-cel pencilled for 2028, Cellectis is entering the window where CMC readiness, process validation, and manufacturing scale-up become the critical path, not clinical outcomes alone. The company's Q1 2026 update, published May 11, positions the allogeneic CAR-T programme as its nearest regulatory inflection point.

The pivotal Phase 2 BALLI-01 trial in relapsed or refractory B-cell acute lymphoblastic leukemia remains ongoing, with a first interim analysis expected in Q4 2026 at n=40. Phase 1 data supporting the dose selection showed 100% overall response rate in the target Phase 2 population, 83% ORR at the recommended Phase 2 dose, and a median overall survival of 14.8 months in MRD-negative complete responders. Rates of grade 3 or higher CRS and ICANS were 2.5% and 5% respectively, a safety profile that will inform the risk-benefit framing in any future 21 CFR Part 211-aligned submission package.

For manufacturing and QA teams, the 2028 BLA horizon means the comparability and lot-release strategy for an off-the-shelf allogeneic product needs to be substantially defined within the next 12 to 18 months. Allogeneic CAR-T introduces distinct CMC challenges relative to autologous therapies: master cell bank qualification, vector integration consistency, and cryopreservation validation all require prospective data packages that regulators will scrutinise under ICH Q10 quality system expectations.

Separately, the eti-cel Phase 1 NATHALI-01 trial in relapsed or refractory non-Hodgkin lymphoma reported 88% ORR and 63% complete response rate at the current dose level, with 93% of subjects having received prior CD19 CAR-T. A full Phase 1 dataset, including low-dose IL-2 combination cohorts, is expected in Q4 2026, data that will shape the dose-ranging rationale for any subsequent pivotal design.

On the partnered side, Allogene reported interim pivotal data from the ALPHA3 trial of cema-cel, originally developed by Cellectis as UCART19. Of 24 patients, 58.3% in the cema-cel arm achieved MRD negativity versus 16.7% in the observation arm, with no cases of CRS, ICANS, GvHD, or treatment-related serious adverse events. Study accrual is expected to complete by end of 2027, with a primary event-free survival analysis anticipated in mid-2028.

Cellectis reported cash, cash equivalents, and fixed-term deposits of $188 million as of March 31, 2026, providing runway into Q4 2027, a timeline that aligns tightly with the lasme-cel interim readout but leaves limited buffer for manufacturing remediation or regulatory response cycles ahead of the 2028 filing.

The Q4 2026 interim analysis for BALLI-01 will be the first measurable checkpoint against which the 2028 BLA timeline can be assessed with any precision.

Source: Cellectis via press release, May 11, 2026.